Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts CNCE Hot Sheet
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming virtual investor conferences:
- The H.C. Wainwright Global Life Sciences Conference on March 9, 2021, on-demand beginning at 7:00 a.m. ET; and
- The Oppenheimer Virtual 31st Annual Healthcare Conference on March 17, 2021 at 9:20 a.m. ET.
A live webcast of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Concert’s website for two weeks following the presentation.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005055/en/
Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com
Source: Concert Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recu
- C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021
- 24 CHILDREN FROM AROUND THE WORLD NAMED AS FINALISTS IN LIONS CLUBS INTERNATIONAL’S PEACE POSTER CONTEST
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!